A new grading system for ototoxicity in adults

Annals of Otology, Rhinology and Laryngology

Volumn 123, Issue 10, 2014, Pages 711-718

  Theunissen, Eleonoor A R ^a   Dreschler, Wouter A ^b   Latenstein, Merel N ^a   Rasch, Coen R N ^b   Van Der Baan, Sieberen ^b   De Boer, Jan Paul ^a   Balm, Alfons J M ^a   Zuur, Charlotte L ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Grading criteria; Grading scales; Hearing loss; Ototoxicity

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; AIR CONDUCTION; ARTICLE; ASSESSMENT OF HUMANS; AUDITORY THRESHOLD; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS VERSION 4; CONTROLLED STUDY; CONVERSATION; DRUG MEGADOSE; FEMALE; HEAD AND NECK CANCER; HEARING ACUITY; HEARING IMPAIRMENT; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; OTOTOXICITY; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RADIATION DOSE; SPEECH INTELLIGIBILITY; SPEECH PERCEPTION; COHORT ANALYSIS; FEASIBILITY STUDY; HEAD AND NECK NEOPLASMS; HEARING LOSS; MIDDLE AGED; PHYSIOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; CHEMORADIOTHERAPY; CISPLATIN; COHORT STUDIES; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, INTENSITY-MODULATED; SEVERITY OF ILLNESS INDEX; SPEECH PERCEPTION;

EID: 84928706921     PISSN: 00034894     EISSN: 1943572X     Source Type: Journal    
DOI: 10.1177/0003489414534010     Document Type: Article

References (32)

1. Obasikene G, Adobamen P, Okundia P, Ogusi FO. Prevalence of ototoxicity in University of Benin Teaching Hospital, Benin City: a 5-year review. Niger J Clin Pract. 2012;15(4):453-457.
2. Schacht J, Talaska AE, Rybak LP. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken). 2012;295(11):1837-1850.
3. Ding D, Allman BL, Salvi R. Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken). 2012;295(11):1851-1867.
4. Vyskocil A, Truchon G, Leroux T, et al. A weight of evidence approach for the assessment of the ototoxic potential of industrial chemicals. Toxicol Ind Health. 2012;28(9):796-819.
5. Bhandare N, Jackson A, Eisbruch A, et al. Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys. 2010;76(3) (suppl):S50-S57.
6. Zuur CL, Simis YJ, Lansdaal PE, et al. Audiometric patterns in ototoxicity of intra-Arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol Neurootol. 2006;11(5):318-330.
7. Zuur CL, Simis YJ, Lansdaal PE, et al. Ototoxicity in a randomized phase III trial of intra-Arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol. 2007;25(24):3759-3765.
8. Zuur CL, Simis YJ, Lamers EA, et al. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-And-neck tumors. Int J Radiat Oncol Biol Phys. 2009;74(2):490-496.
9. Zuur CL, Simis YJ, Verkaik RS, et al. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol. 2008;89(1):38-43.
10. Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R. Radiotherapy-induced ear toxicity. Cancer Treat Rev. 2003;29(5):417-430.
11. Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol. 2006;24(12):1904-1909.
12. Petsuksiri J, Sermsree A, Thephamongkhol K, et al. Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients. Radiat Oncol. 2011;6:19.
13. Prestes R, Daniela G. Impact of tinnitus on quality of life, loudness and pitch match, and high-frequency audiometry. Int Tinnitus J. 2009;15(2):134-138.
14. U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). Version 4.0. http://www.eortc.be/services/doc/ctc/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Published May 28, 2009. Accessed April 20, 2014.
15. American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;36:11-19.
16. Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408-2417.
17. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010;28(10):1788-1795.
18. Gurney JG, Bass JK. New International Society of Pediatric Oncology Boston ototoxicity grading scale for pediatric oncology: still room for improvement. J Clin Oncol. 2012;30(19):2303-2306.
19. Neuwelt EA, Brock P. Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol. 2010;28(10):1630-1632.
20. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19(4):295-300.
21. Chang KW. Clinically accurate assessment and grading of ototoxicity. Laryngoscope. 2011;121(12):2649-2657.
22. Gurgel RK, Jackler RK, Dobie RA, Popelka GR. A new standardized format for reporting hearing outcome in clinical trials. Otolaryngol Head Neck Surg. 2012;147(5):803-807.
23. Pavlovic CV. Use of the articulation index for assessing residual auditory function in listeners with sensorineural hearing impairment. J Acoust Soc Am. 1984;75(4):1253-1258.
24. Mueller HG, Killion MC. An easy method for calculating the articulation index. Hearing Journal. 1990;43(9):1-4.
25. Fausti SA, Frey RH, Erickson DA, Rappaport BZ, Cleary EJ, Brummett RE. A system for evaluating auditory function from 8000-20 000 Hz. J Acoust Soc Am. 1979;66(6):1713-1718.
26. Fausti SA, Schechter MA, Rappaport BZ, Frey RH, Mass RE. Early detection of cisplatin ototoxicity. Selected case reports. Cancer. 1984;53(2):224-231.
27. DellAringa AH, Isaac ML, Arruda GV, et al. Audiological findings in patients treated with radio-And concomitant chemotherapy for head and neck tumors. Radiat Oncol. 2009;4:53.
28. Gurgel RK, Popelka GR, Oghalai JS, Blevins NH, Chang KW, Jackler RK. Is it valid to calculate the 3-kilohertz threshold by averaging 2 and 4 kilohertz? Otolaryngol Head Neck Surg. 2012;147(1):102-104.
29. Dobie RA. Audiometric threshold shift definitions: simulations and suggestions. Ear Hear. 2005;26(1):62-77.
30. Zuur CL, Simis YJ, Lansdaal PE, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-And-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys. 2007;68(5):1320-1325.
31. International Organization for Standardization. Acoustics-Statistical Distribution of Hearing Thresholds as a Function of Age. Geneva, Switzerland: International Organization for Standardization; 2000. Reference number ISO 7029:2000 (E).
32. Newman CW, Weinstein BE, Jacobson GP, Hug GA. The Hearing Handicap Inventory for adults: psychometric adequacy and audiometric correlates. Ear Hear 1990;11:430-433.